MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’…
MaaT PharmaMarch 19, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…
MaaT PharmaMarch 7, 2024
MaaT Pharma Releases its 2024 Financial Calendar Lyon, France, March 7, 2024 –6:00pm CET –…
MaaT PharmaMarch 7, 2024
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial…
MaaT PharmaMarch 5, 2024
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial…
MaaT PharmaFebruary 29, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…
MaaT PharmaFebruary 8, 2024
MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux Lyon, France,…
MaaT PharmaJanuary 22, 2024
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaJanuary 8, 2024
MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations…
MaaT PharmaDecember 12, 2023
